Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors
Authors
Keywords
Pixatimod, PG545, Immunomodulatory, Tumor-associated macrophage, Dendritic cell, NK cell, T cell, PD-1 inhibition, Toxicology, Pharmacokinetics, Clinical trial, Pancreatic adenocarcinoma
Journal
Journal for ImmunoTherapy of Cancer
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-06-14
DOI
10.1186/s40425-018-0363-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours
- (2018) Keith Dredge et al. BRITISH JOURNAL OF CANCER
- Opposing Functions of Heparanase-1 and Heparanase-2 in Cancer Progression
- (2018) Israel Vlodavsky et al. TRENDS IN BIOCHEMICAL SCIENCES
- Inhibition of Heparanase in Pediatric Brain Tumor Cells Attenuates their Proliferation, Invasive Capacity, and In Vivo Tumor Growth
- (2017) Argyris Spyrou et al. MOLECULAR CANCER THERAPEUTICS
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
- (2017) Floris Dammeijer et al. Cancer Immunology Research
- The Heparanase Inhibitor PG545 Attenuates Colon Cancer Initiation and Growth, Associating with Increased p21 Expression
- (2017) Preeti Singh et al. NEOPLASIA
- Combination immunotherapy: a road map
- (2017) Patrick A. Ott et al. Journal for ImmunoTherapy of Cancer
- The Role of Heparanase in the Pathogenesis of Acute Pancreatitis: A Potential Therapeutic Target
- (2017) Iyad Khamaysi et al. Scientific Reports
- Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models
- (2016) Julie K. Jang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Breakthrough: Macrophage-Directed Cancer Immunotherapy
- (2016) C. D. Mills et al. CANCER RESEARCH
- Heparanase: From basic research to therapeutic applications in cancer and inflammation
- (2016) Israel Vlodavsky et al. DRUG RESISTANCE UPDATES
- Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy
- (2016) Ralph D. Sanderson et al. FEBS Journal
- Heparanase Promotes Glioma Progression and Is Inversely Correlated with Patient Survival
- (2016) Soumi Kundu et al. MOLECULAR CANCER RESEARCH
- Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis
- (2016) Marina Weissmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+T cells
- (2016) Shu Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade
- (2016) Nina Eissler et al. OncoImmunology
- Heparanase Enhances Tumor Growth and Chemoresistance by Promoting Autophagy
- (2015) Anna Shteingauz et al. CANCER RESEARCH
- PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples
- (2015) Boris Winterhoff et al. EUROPEAN JOURNAL OF CANCER
- Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation
- (2015) Todd V. Brennan et al. JOURNAL OF CLINICAL INVESTIGATION
- Priming of Human Resting NK Cells by Autologous M1 Macrophages via the Engagement of IL-1β, IFN-β, and IL-15 Pathways
- (2015) Irene Mattiola et al. JOURNAL OF IMMUNOLOGY
- The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine
- (2015) Deok-Beom Jung et al. Oncotarget
- HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer
- (2015) Susmita Mondal et al. Oncotarget
- Heparanase Cooperates with Ras to Drive Breast and Skin Tumorigenesis
- (2014) I. Boyango et al. CANCER RESEARCH
- Macrophage Polarization in Pancreatic Carcinoma: Role of Heparanase Enzyme
- (2014) Esther Hermano et al. JNCI-Journal of the National Cancer Institute
- Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
- (2014) K. Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Beware of NK cells in pre-clinical metastasis models
- (2013) L. A. Coupland et al. CLINICAL & EXPERIMENTAL METASTASIS
- The heparanase/syndecan-1 axis in cancer: mechanisms and therapies
- (2013) Vishnu C. Ramani et al. FEBS Journal
- PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer
- (2013) K. T. Ostapoff et al. MOLECULAR CANCER THERAPEUTICS
- Heparanase promotes lymphangiogenesis and tumor invasion in pancreatic neuroendocrine tumors
- (2013) K E Hunter et al. ONCOGENE
- Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues
- (2013) Edward Hammond et al. FEBS Open Bio
- Rational combinations of immunotherapeutics that target discrete pathways
- (2013) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Discovery of PG545: A Highly Potent and Simultaneous Inhibitor of Angiogenesis, Tumor Growth, and Metastasis
- (2012) Vito Ferro et al. JOURNAL OF MEDICINAL CHEMISTRY
- PG545, a Heparan Sulfate Mimetic, Reduces Heparanase Expression In Vivo, Blocks Spontaneous Metastases and Enhances Overall Survival in the 4T1 Breast Carcinoma Model
- (2012) Edward Hammond et al. PLoS One
- PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models
- (2011) K Dredge et al. BRITISH JOURNAL OF CANCER
- Heparanase: a universal immunotherapeutic target in human cancers
- (2011) Ya-Fei Zhang et al. DRUG DISCOVERY TODAY
- Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor
- (2011) E. Narni-Mancinelli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy
- (2009) K. Dredge et al. INVESTIGATIONAL NEW DRUGS
- Intratumoral But Not Systemic Delivery of CpG Oligodeoxynucleotide Augments the Efficacy of Anti-CD20 Monoclonal Antibody Therapy Against B Cell Lymphoma
- (2009) David J. Betting et al. JOURNAL OF IMMUNOTHERAPY
- High Expression of Heparanase is Significantly Associated with Dedifferentiation and Lymph Node Metastasis in Patients with Pancreatic Ductal Adenocarcinomas and Correlated to PDGFA and Via HIF1a to HB-EGF and bFGF
- (2008) Andreas-Claudius Hoffmann et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
- (2008) A M Krieg ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started